Search results
Results from the WOW.Com Content Network
Ramosetron is a serotonin 5-HT 3 receptor antagonist for the treatment of nausea and vomiting. [1] Ramosetron is also indicated for a treatment of "diarrhea-predominant irritable bowel syndrome in male and women". [2]
The pharmacokinetics of dienogest are linear; single oral doses of dienogest were found to result in maximal levels of 28 ng/mL with 1 mg, 54 ng/mL with 2 mg, 101 ng/mL with 4 mg, and 212 ng/mL with 8 mg. [7] The corresponding area-under-the-curve levels were 306, 577, 1153, and 2293 ng/mL, respectively. [7]
1.name 2.age 3.sex 4.occupation 5.address 6.chief complaint of patient 7.history of patient:- present illness history past illness history medical history family history personal history 8.pain site of pain nature of pain quantity of pain on v.a.s scale type of pain 9.examination active movement passive movement 10.observation gait posture r.o ...
On May 11, 2019, Teva Pharmaceuticals USA was one of 19 drug companies sued for price fixing in the United States by 44 states for inflating its prices, sometimes up to 1000%, in an illegal agreement among it and its competitors. [7] In June 2021, Teva agreed to pay $925M to settle allegations it had engaged in price fixing in Mississippi. [109]
The R&D group at teva api consists of a team of over 760 top scientists located in 7 development centers worldwide: A large center in Israel (synthetic products and peptides), a large center in Hungary (fermentation and semi-synthetic products), and a facility in India and additional sites in Italy, Croatia, Mexico and the Czech Republic (development of high potency API). teva api's R&D ...
Kaye built Norton Healthcare Ltd., a UK generic pharmaceutical company, which was acquired by Ivax Corporation in 1990. [2] He became chairman of Ivax Pharmaceuticals UK. In 2006 Ivax was sold to Teva Pharmaceuticals for $7.4 billion. [2] In 2002 Ivax was the largest supplier of generic drugs to the NHS. [1]
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Donate
Moxonidine is a new-generation alpha-2/imidazoline receptor agonist antihypertensive drug licensed for the treatment of mild to moderate essential hypertension. [ 5 ] [ 6 ] It may have a role when thiazides , beta-blockers , ACE inhibitors , and calcium channel blockers are not appropriate or have failed to control blood pressure.